Analystreport

Pacific Biosciences of California (NASDAQ: PACB) had its price target raised by analysts at Piper Sandler from $6.00 to $12.00. They now have an "overweight" rating on the stock.

Pacific Biosciences of California, Inc.  (PACB) 
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.pacificbiosciences.com